- 06-08-2020Online Events - Autumn Programme
- 05-08-2020AAV Gene Therapy For Neuronopathic Gaucher Disease
- 05-08-2020IGD2020: Home Therapy Webinar
- 05-08-2020Ex Vivo Gene Therapy For GD1
AVROBIO has announced a partnership with Saladax Biomedical to develop a new blood test that will simplify and streamline therapeutic drug monitoring (TDM) during the conditioning phase of the lentiviral gene therapy process.
Full details can be found on their press release here
AVROBIO has previously received notice of clearance from the FDA regarding an Investigational New Drug (IND) application for AVR-RD-02, its investigational gene therapy for the treatment of Gaucher disease and has received consent from the first patient to enroll in its global Phase 1/2 trial. The GAU-201 trial is actively recruiting in Australia and Canada, with additional sites planned in the United States.